Bicycle Therapeutics (BCYC)

Healthcare · Biotechnology
$3.89 +2.10% on the day Market cap $255M 52-week range $3.33 to $9.10 Prices as of Oct 11, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Bicycle Therapeutics's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

F

Five factors scored 1 to 9 from BCYC's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation6
Profitability0
Growth0
Financial health9
Cash efficiency0

Results from SEC filings

Fiscal years, from Bicycle Therapeutics's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.

Fiscal year20212022202320242025
Revenue$12M$14M$27M$35M$73M
Net income-$67M-$113M-$181M-$169M-$219M
Free cash flow-$17M-$105M-$64M-$166M-$252M
EPS (diluted)-$2.67-$3.80-$5.08-$2.90-$3.16
Operating margin-561.0%-806.6%-704.1%-595.0%-340.4%

Superinvestors who own BCYC

From each investor's latest 13F filing (what a 13F shows). 1 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Murray Stahl
Horizon Kinetics LLC
Trimmed $53,3560.00%Q2 2026

Insider buying

Open-market purchases by Bicycle Therapeutics's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of BCYC in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when BCYC trades at or below it.

$

New accounts get 7 days of Pro, price alerts included. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are Bicycle Therapeutics insiders buying the stock?

No open-market insider purchases of BCYC in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Bicycle Therapeutics?

1 of the superinvestors Investingly tracks hold BCYC in their latest 13F, including Murray Stahl.

Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.